Uncategorized

The FDA must put biotech at its center or continue to cede early research to China

Published

on

Last month, the FDA launched TrialBlazer, intended to streamline the IND path and bring early clinical trials and medical innovation home to the U.S. It’s a start, but new agency leadership must see it through.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version